Rafael Holdings Inc
Company Profile
Business description
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
Contact
520 Broad Street
NewarkNJ07102
USAT: +1 212 658-1450
Sector
Real Estate
Stock type
Cyclical
Industry
Real Estate Services
Fiscal Year End
31 July 2027
Employees
23
Stocks News & Analysis
stocks
Anthropic and OpenAI face commodification threats. Here’s what to watch for
stocks
Berkshire Hathaway: Abel pushes into new territory with Bending Spoons investment
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,944.20 | 31.50 | -0.35% |
| CAC 40 | 7,809.66 | 58.39 | -0.74% |
| DAX 40 | 25,117.03 | 202.74 | -0.80% |
| Dow JONES (US) | 51,966.03 | 36.38 | -0.07% |
| FTSE 100 | 10,685.46 | 79.23 | -0.74% |
| HKSE | 23,867.74 | 319.09 | -1.32% |
| NASDAQ | 26,430.89 | 290.85 | 1.11% |
| Nikkei 225 | 64,075.42 | 841.28 | -1.30% |
| NZX 50 Index | 13,631.69 | 20.38 | -0.15% |
| S&P 500 | 7,690.73 | 31.29 | 0.41% |
| S&P/ASX 200 | 8,816.90 | 28.80 | -0.33% |
| SSE Composite Index | 3,735.37 | 4.45 | 0.12% |